




RealRate

PHARMACEUTICAL 2022

Arbutus Biopharma Corp
Rank 245 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Arbutus Biopharma Corp is the variable Research and Development, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is -103%, being 173% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	160,661
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,221
Liabilities, Non-Current	2,231
Other Assets	37,841
Other Compr. Net Income	-164
Other Expenses	1,872
Other Liabilities	21,594
Other Net Income	-2,725
Property and Equipment	5,983
Research and Development	65,502
Revenues	10,988
Selling, General and Administrative Expense	17,136

Output Variable	Value in 1000 USD
Assets	204,485
Liabilities	35,046
Expenses	84,510
Stockholders Equity	169,439
Net Income	-76,247
Comprehensive Net Income	-76,329
Economic Capital Ratio	-103%